BioLargo Subsidiary BEST Featured in Chemical Engineering Magazine for PFAS Breakthrough
Rhea-AI Summary
BioLargo (OTCQX:BLGO) announced its subsidiary BioLargo Equipment Solutions & Technologies was featured in Chemical Engineering for its Aqueous Electrostatic Concentrator (AEC) PFAS treatment, described as producing "nearly zero waste" while removing long-, short-, and ultra-short-chain PFAS. The company also delivered an AEC system to the Lake Stockholm, New Jersey drinking water facility and is supporting provisioning, integration, and commissioning with the general contractor.
Company statements note the delivery is the final stage before the AEC goes live for the Lake Stockholm community and reference New Jersey settlements exceeding $2.5 billion that support PFAS cleanup efforts.
Positive
- AEC removes long-, short-, and ultra-short-chain PFAS
- Nearly zero waste PFAS treatment per Chemical Engineering feature
- Delivered AEC system to Lake Stockholm drinking water facility
- Company to support commissioning and integration on site
Negative
- None.
News Market Reaction
On the day this news was published, BLGO declined 0.36%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
BLGO was down 0.72% while chemical peers were mixed: several declined (e.g., KBLB -3.82%, NNOMF -3.43%) and one notable gainer was GMGMF at +2.19%, pointing to stock-specific rather than broad sector-driven trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Technology deployment update | Positive | -0.4% | AEC PFAS technology featured and system delivered for Lake Stockholm facility. |
| Nov 21 | Conference presentation | Positive | +1.1% | Management presenting at NobleCon 21 on financial results and developments. |
| Nov 17 | Earnings release | Neutral | +0.1% | Q3 2025 operating and financial results reported to the market. |
| Nov 13 | Earnings call notice | Neutral | +0.5% | Announcement of webcast and call to discuss Q3 2025 results. |
| Nov 13 | Strategic partnership | Positive | +0.5% | Clyra Medical alliance to distribute ViaCLYR wound irrigation nationwide. |
Recent news, including partnerships and conference appearances, often saw modestly positive price reactions, while this PFAS-focused highlight coincided with a slight decline, suggesting occasional divergence even on constructive updates.
This announcement continues a run of operational and visibility milestones for BioLargo in late 2025. Earlier in November, the company disclosed a Q3 2025 earnings release and hosted an associated webcast and conference call. A subsidiary also formed a strategic distribution alliance to launch ViaCLYR™ nationwide in early 2026. On November 21, 2025, BioLargo highlighted its participation at NobleCon 21. Today’s feature on the AEC PFAS treatment system and delivery to Lake Stockholm builds on that narrative of commercialization and outreach.
Market Pulse Summary
This announcement highlights external recognition of BioLargo’s AEC platform for PFAS treatment and confirms delivery of a system to the Lake Stockholm, New Jersey drinking water facility. It underscores the technology’s focus on removing multiple PFAS chain lengths with minimal waste generation and ties into New Jersey’s PFAS cleanup efforts backed by more than $2.5 billion in settlements. Investors may track commissioning progress at Lake Stockholm and additional commercial deployments as key indicators of traction.
Key Terms
pfas technical
AI-generated analysis. Not financial advice.
Lake Stockholm, NJ AEC System Delivered and Preparing to Go Live
WESTMINSTER, CALIFORNIA / ACCESS Newswire / December 3, 2025 / BioLargo, Inc. (OTCQX:BLGO), a cleantech innovator focused on sustainable water and environmental solutions, announced that its subsidiary, BioLargo Equipment Solutions & Technologies, Inc., has been prominently featured in Chemical Engineering magazine for its advances in electrostatic PFAS ("forever chemicals") treatment technology.
The article, titled "Electrostatic PFAS Capture Produces Nearly Zero Waste," highlights the performance benefits of BioLargo's Aqueous Electrostatic Concentrator (AEC) platform, including its ability to remove long-, short-, and ultra-short-chain PFAS while generating dramatically less waste than conventional treatment methods.
(Chemical Engineering: https://www.chemengonline.com/electrostatic-pfas-capture-produces-nearly-zero-waste/)
In parallel, BioLargo has delivered the AEC system purchased by Lake Stockholm Systems, Inc. to the community drinking water treatment facility in Lake Stockholm, New Jersey. The team will assist wherever needed to support general contractor and the client to provision, integrate, and commission the system.
"This milestone represents the last stage before the AEC begins serving the Lake Stockholm community, and everyone is excited to work through to completion the provisioning phase" said Tonya Chandler. "We're proud to see our work recognized by Chemical Engineering, and we're equally proud to as we help deliver affordable, PFAS free water to the world. The State of New Jersey is a leader in PFAS clean-up efforts. Recent landmark settlements of more than
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire
FAQ
What did BioLargo (BLGO) announce on December 3, 2025 about PFAS technology?
Has BioLargo (BLGO) deployed an AEC system to a municipal water plant?
What performance benefit did Chemical Engineering highlight about BioLargo's AEC?
Will BioLargo (BLGO) assist with the Lake Stockholm AEC installation timeline?
Does the announcement mention funding or settlements supporting PFAS cleanup in New Jersey?
